Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
Humacyte presented positive Phase 3 results from its V012 study, showing its bioengineered blood vessel (ATEV) outperformed the standard of care (AV fistula) for women on dialysis. Patients receiving ATEV remained catheter-free for an average of 220 days in the first year, compared to 129 days for those with AV fistulas, a statistically significant difference (p=0.00070). Infection rates were also significantly lower in the ATEV group (6 per 100 patient years vs. 23 for AV fistula).
Key figures
- Drug Name
- ATEV (acellular tissue engineered vessel)
- Phase Of Trial
- Phase 3
- P value primary
- 0.0007
- Infection rate avf
- 23 per 100 patient years
- Infection rate atev
- 6 per 100 patient years
- Six month patency avf
- 65.0%
- Catheter free days avf
- 129
- Six month patency atev
- 87.5%
- Catheter free days atev
- 220
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.